Semaglutide Shows Major Health Benefits Beyond Weight Loss

New studies reveal that the active ingredient in Ozempic and Wegovy significantly reduces risks of kidney disease, heart attacks, and death.

Semaglutide injections reduce the risk of severe kidney events by 24% in patients with chronic kidney disease and type 2 diabetes.
The drug also lowers the risk of major cardiovascular events by 18% and all-cause mortality by 20%.
Research indicates benefits extend to patients without diabetes, suggesting broader applications for kidney protection.
Experts highlight potential economic impacts, with reduced healthcare costs and improved patient outcomes.
The findings support expanding the use of semaglutide for treating multiple chronic conditions.